|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.22 USD | +1.11% |
|
+1.04% | +32.38% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Protein and Genome Sequence Products | |||||||||
Operating Income | -104M | -232M | -468M | -570M | -924M | ||||
Net Income | -100M | -223M | -402M | -464M | -767M | ||||
D&A | 3.46M | 9.2M | 10.17M | 15.84M | 24.86M | ||||
EBT | -100M | -223M | -402M | -464M | -767M | ||||
CAPEX | -6.56M | -5.85M | -67.88M | -119M | -56.97M | ||||
Interest Expense | -7K | -2K | - | - | - | ||||
Total Assets | 324M | 1.01B | 1.41B | 3.51B | 3B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Total Assets | - | - | - | 157M | 218M | ||||
EBT | -100M | -223M | -402M | - | - | ||||
Operating Income | -104M | -232M | -468M | - | - | ||||
Net Income | -100M | -223M | -402M | - | - | ||||
CAPEX | -6.56M | -5.85M | -67.88M | - | - | ||||
D&A | 3.46M | 9.2M | 10.17M | - | - | ||||
Interest Expense | -7K | -2K | - | - | - | ||||
Total Assets | 324M | 1.01B | 1.41B | 40.8M | 39.7M |
- Stock Market
- Equities
- PCVX Stock
- Financials Vaxcyte, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
